Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show g ...

Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time gene therapy for the treatment of patients with vision loss due to a ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of 10.7%, reaching US$16.36 ...

The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of ...

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D ...

A doctor who was ordered to pay Blue Cross and Blue Shield of Louisiana nearly $130,000 for improper billing practices failed to convince a federal judge to hear his case and undo the arbitration ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...